Home  |  Publications  |  Conferences   |  Join  |  Contact
                            
 
ISSN: 2471-9552

Immunotherapy: Open Access

Regulatory and FDI Guidelines for Immunotherapeutics
Search results for Regulatory and FDI Guidelines for Immunotherapeutics
 
 
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes
700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
 
 
 
 
 
 
Share this page  Facebook  Twitter  LinkedIn  Google+  Pinterest   Blogger

Immunotherapeutic products are target specific and intended for minimal side effects so certain rules must be followed by manufacturer given by FDA under FD&C act and its amendements. FDA ( Food and Drug Administration) regulatory body regulates production and post-production activities of products in conjugation with CBER (Centre for Biologics Evaluation and Research), CDER ( Centre for Drug Evaluation and Research), OBP (Office of Biotechnology Products) and OHOP (Office of Hematology and Oncology Products).

They evaluate for purity, potency, viability, quality of raw materials and reagents used in the manufacture. CBER/OCTGT handles cancer vaccines and cell based immunotherapeutic products. CDER reviews monoclonal antibodies.

Related Journals of Regulatory and FDI Guidelines for Immunotherapeutics

Immunotherapy: Open Access, Immunooncology journal, Immunobiology journal, Immunology Journal, Immunome Research journal, The Journal of Allergy and Clinical Immunology, World Allergy Organization Journal, The Lancet, HHS Public Access, Clinical and Translational Allergy.